Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells

Transplantation

Volumn 69, Issue 7, 2000, Pages 1341-1347

  Davison, Glenda M ^a   Novitzky, Nicolas ^a,c   Kline, Almaree ^a   Thomas, Valda ^a   Abrahams, Louise ^a   Hale, Geoffrey ^b   Waldmann, Herman ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE SYSTEM; IMMUNOPHENOTYPING; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0034655759     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200004150-00022     Document Type: Article

References (35)

1. Arnold R, Schmeister T, Heit W, et al. Hemotopoietic reconstitutiton after bone marrow transplantation. Exp Hematol 1986; 14: 271.
2. Da W-M, Ma DD, Biggs JC. Studies of hematopoietic stromal fibroblastic colonies in patients undergoing bone marrow transplantation. Exp. Hematol 1986; 14: 266.
3. Novitzky N, Mohamed R. Alterations in both the hematopoietic microenvironment and the progenitor cell population follow the recovery from myeloablative therapy and bone marrow transplantation. Exp.Hematol 1995; 23: 1661.
4. Novitzky N, Mohammed R. Alterations in the progenitor cell population follow recovery from myeloablative therapy and bone marrow transplantation. Exp Hematol 1997; 25: 471.
5. Storek J, Witherspoon RP, Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant 1995; 16: 413.
6. Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 19.
7. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729.
8. Storb R, Deeg HJ, Fisher L, et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988; 71: 293.
9. Chasty RC, Lamb, WR, Gallati H, et al. Serum cytokine levels in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1993; 12: 331.
10. Hale G, Bright S, Chumbley G, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62: 873.
11. Hale G, Xia M-Q, Tighe HP, et al. The CAMPATH-1 antigen (CDw 52). Tissue Antigens 1990; 35: 118.
12. Hale G, Waldmann H. CAMPATH-1 Monoclonal antibodies in bone marrow transplantation. J Hematotherapy 1994; 3: 15.
13. Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994; 13: 597
14. Waldmann H, Polliak A, Hale G, et al. Elimination of graft vs host disease by in vitro t cell depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; 2: 483.
15. Roberts MM, To LB, Gillis D et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 469.
16. Jacobs P, Wood L, Fullard L, et al. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant 1994; 13: 763.
17. Thomas, E.D, Storb R, Clift R A, et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 895.
18. Bass EB, Powe NR, Goodman SN, et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta analysis. Bone Marrow Transplant. 1993; 12: 273.
19. Novitzky N, Kruger W, Mohamed R. Cryopreservation of the bone marrow from patient's with acute myeloid leukemia leads to functional abnormalities. Eur J Haematol 1999; 62: 83.
20. Bollinger PB, Drewinko B, Brailas CD, et al. The Technicon H*1 TM - an automated hematology analyzer for today and tomorrow. Complete blood count parameters. Am J Clin Pathol 1987; 87: 71.
21. Storb R, Etzioni R, Anasett, C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941.
22. Gondo H, Minemats T, Harada M, et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol 1994; 86: 130.
23. Giralt SA, Kolb H. J Donor lymphocyte infusions. Curr Opin Oncol 1996; 8: 96.
24. Einsele H, Ehninger G, Steidle M, et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993; 82: 1672.
25. Rocha B, Vassalli P, Guy-Grand D. Thymic and extrathymic origins of gut intraepithelial lymphocyte populations in mice. J Exp Med 1994; 180: 681.
26. Roux E, Helg C, Dumont-Girard F, et al. Analysis of T-cell repopulation after allogeneic marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996; 87: 3984.
27. Dulude G. Brochu S. Fontaine P, et al. Thymic and extrathymic differentiation and expansion of T lymphocytes following bone marrow transplantation in irradiated recipients. Experimental Hematology, 1997; 25: 992.
28. Lowdell MW, Craston R, Ray N, et al. The effect of T cell depletion with Campath 1 M on immune reconstitution after chemotherapy and allogeneic bone marrow trasnplantation as treatement for leukemia. Bone Marrow Transplant 1998; 21: 679.
29. Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two dose regimen of influenza vaccine in allogeneic T cell depleted and autologous BMT recipients. Bone Marrow Transplant 1993; 11: 1.
30. Keever CA, Small TN, Flomenberg N, et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrows with recipients of conventional grafts. Blood 1989; 73: 1340.
31. Bomberger C, Singh-Jairam M, Rodey G, et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS sorted CD 34+ haematopoietic progenitors. Blood 1998; 91: 2588.
32. Leitenberg D, Rappeport JM, Smith BR. B cell precursor bone marrow reconstitution after bone marrow transplantation. Am J Clin Pathol 1994; 102: 231.
33. Powles R, Singhal S, Treleaven J, et al. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998; 91: 3481.
34. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response?. Bone Marrow Transplant 1995; 15: 591.
35. Novitzky N, Rubinstein R, Hallett J, et al. Adoptive immunotherapy for chronic myelogenous leukaemia patients relapsing after allogeneic bone marrow transplantation using T-cell depletion with Campath 1G (Abstract). Br J Haematol 1998; 102. (Suppl.1): P-0850.